Poseida Therapeutics (PSTX)
(Real Time Quote from BATS)
$3.63 USD
+0.29 (8.68%)
Updated Jul 25, 2024 03:50 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PSTX 3.63 +0.29(8.68%)
Will PSTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PSTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PSTX
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates
PSTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
Universal Health Services (UHS) Q4 Earnings and Revenues Top Estimates
Other News for PSTX
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $10 (or More), Say Analysts
12 Health Care Stocks Moving In Tuesday's After-Market Session
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Poseida Therapeutics Partners With Astellas: Worth Watching For Now